This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease…

Parkinson Disease Psychosis

~Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT05824728

Phase 4

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors co…

Neurodegenerative DiseasesParkinson DiseaseParkinson Disease Psychosis

~Estimated

~$10 – $6,250

Vanderbilt University Medical CenterNCT05357612